Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for exercise capacity in pulmonary arterial hypertension with overweight or obesity
ACTRN12626001139369Phase 3Not yet recruiting
- Sponsor
- Sydney Local Health District
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of semaglutide in pulmonary arterial hypertension (PAH), obesity and Overweight (2 arms), sponsored by Sydney Local Health District. Primary endpoint: 6-minute walk distance. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)obesityOverweight
Beyond the preview
Go deeper on ACTRN12626001139369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001139369.